

Continue

Blastic plasmacytoid dendritic cell neoplasm case report

1. Saedeh D, Kurban M, Abbas O plasmicyoid dandritic cell role in cataneous malignant. J. Dermetol Science 2016;83:3-9. [PubMed] [Google Scholar] 2. Dantas Fe, De Almeida Vieira CA, De Castro CC, NATO GC, Matos DM. Blastic plazacytoid dendritic cell neoplasm without cuticinpartase partnership: a rare disease with a rare presentation. Acta Oncol. 2012;51:139–41. [PubMed] [Google Scholar] 3. Zhang YW, Zheng Jh, Chen XL, Xiao F, Chen FY. Blastic Plazacytoid Dandritic Cell Neoplasm: A Case Report and Literature Review. Exp Ther Made. 2016;12:319-22ı [PMC free articles] [PubMed] [Google Scholar] 4. Chow YH, Lin RY, Li MS, Wu HP, Lin CP. Injury-like cutaneous lesions as the initial presentation of blastic plazacytoid dendritic cell neoplasm. Dermetol sin. 2014;24:101–6. [Google Scholar] 5. Kakar Döger F, Dikicioğlu Çetin E, Hekimgil M, Özdoğan Uslu M, Kadıköylü G, Özsan N, et al. Plasmolcytoid dandritic cell tumors: a case report. Turk Jay Hematol. 2011;28:312–6. [PubMed] [Google Scholar] 6. Lee Y, Lee Z, Lin HL, Chen XH, Lee B. Primary Cutanese Blastic Plazacytoid Dandritic Cell Neoplasms Without Extuteness Expression: Case Report and Literature Review. Pathol re pract. 2011;207:55–9. [PubMed] [Google Scholar] 7. Gurgen J, Hogan D, Muller K, Phool J, Sexton W. CD4+CD56 + tdT + haematoderm (previously called Blastic Natural Killer Cell Lymphoma) In a patient with chronic human T-cell leukaemia virus type 1 infection: a previously unreported association. BR J Dermetol. 2010;162:1395–7. [PubMed] [Google Scholar] 8. Eros N, Marschalko M, Balasa K, Hidwegi B, Szakonyi J, Ilniczky S, et al. Participation of the central nervous system in CD4+/CD56+ hematodermic neoplasm: a report of two cases. J. Neuroncol. 2010;97:301–4. [PubMed] [Google Scholar] 9. Fu Y, Fesler M, Mahmud G, Berneruter K, Zia D, Batanian Jr, et al. Reducing the common removed area of 5q to 6.0 MB in blastic plazacytoid dandritic cell neoplasms. Cancer. 2013;206:293–8. [PubMed] [Google Scholar]10. Rakheja D, Fuda F, Vandergriff T, Boric R, Mederos BC, Frankel AE, et al. Plasma D-2-hydroxyglotaate increased in isocyte dehydrogenase 2-mutated blastic plasmatic dendritic cell neoplasm. We pathol. 2015;46:322–6. [PubMed] [Google Scholar]11. Rauh MJ, Rahman F, Good D, Silverman J, Brennan Mk, Dimov N, et al. With blastic plasmocytoid dandritic cell neoplasm leukemia presentation, lack of cataneous involvement: case series and literature reviews. Luke Res. 2012;36:81-6ı [PubMed] [Google Scholar]12. Lin CY, Wu Mai, Kuo T, Lu Ph Cutner Cutner Blaster Plancyoid Dandritic Cell Neoplasm: A Case Report and Literature Review. Dermetol sin. 2017;35:96–9. [Google Scholar]13. Huang Wai, Liu Yr, Li Ke, Li K, Liu Sh. A woman with rare blastic plasmacytoid dandritic cell neoplasms on the face. Oral Sarg Oral Med Oral Pathol Oral Radiol. 2016;121:e16-8. [PubMed] [Google Scholar]14. Toya T, Nishimoto N, J, Nakagawa M, Nakamura F, Kandabashi K, et al. The first case of the case Plazacytoid dandritic cell neoplasm with MML-ENL rearrangement. Luke Res. 2012;36:117-8ı [PubMed] [Google Scholar] page 2enblicaldecitoid dendritic cell neoplasmothors outpatient age, genderskin explosion, first presence associated with other organs dandtas et al. 2011[2] Woman, 68-liver, spleen, bon marodizi, dyspnia, mental confusion, hepatomegeli, plonemeng, anemiazang et al. 2016[3] Female, 26-bone prochloystopenia, headache, earache and coughchau et al. 2014[4] Male, 41multipal 2-3 cm diameter blues in vilaus intruding patches, plaque, some irregularly shaped violas plaques on the cheeks have minor scratches on his trunk and face such as wounds, bleeding right in the nasal cavity dodoger et al. 2011[5] Well-demarcated erythematus plaques on the male, 622 trunk, 6 purple-red papules on the back and the delimited erythematus plaques on the upper limbs right on the axles-nodeles, purple-red papules on the back and ly et al on the upper end. Papules, 36pinless purple skin papules and plaques on the left hand, anterior chest, and face-papules on the left armmale, 51generalized purple skin nodules- non-itchy pink papules on the head and trunk. Gurden et al 2010[7] men, plaques located on 6300 pelomorphic deep red patches and trunkleft griva, Axillary and bilateral inguinal lymph nodes, kidneys, bone marrow on the left chestros et al.[8] male, 75 generalized erythematus-brown pappulses, plaques, and tumors on the trunnhepatnemengli, left superclave, both accelerary, right engineer, mediastinal, paraatoric lymph, liver, spleen, kidney, supranal glands, bone glands, bone glands, bone glands, , brain, stomach, bladder, rectum, lungs, prostate. Generalized erythematus-brown papules on trunkfikamal, Plaques, and tumors, 69Brownish-red, 2-7 cm large cutness plaques and tumors on the face and trunkinguinal, left cervicle, left mesopharyngeal, retroperitoneal, pelvic lymph nodes, bone marrow, cnsbronish-red, 2-7cm large cutanese plaques and tumors on the face and trunk, cervical and engine lymphadenopathy et affu. 2013[9], 67small ulcer wounds on the left calf, cervical, mestinal, excision, stomach, inguinal lymph nodes, bondispania, fatigue, chest pain, thrombocytopenia, anemia, lymphadenopathy, small ulcer lesions of the left calf. 2015[10] Female, 69cuteus body pink to right shoulder, abdomen, and right lateral lateral marrow infiltration, central nervous system, plehamegnoli, retroperatorial adenopathycutaneus noducrouh et al. 2012 [11] Differs from 1 to 2 cm in diameter on male. , 78-splenomegaly, retroperitoneal lymphadenopathy, bone marrow, peripheral bloodite sweat, weight loss, plymomengli, retroperitoneal lymphapathy, anemia, thrombocytopenia, and leukocytosismale, 82-exilicy lymphadenopathy, hepatospenomemy, peripheral blood, bone pathway Sinus infections, bilateral excision lymphadenopathy, and hepatosplanomemememy, anemia, thrombocytopenia, leukocytosismale, 84-kidney, excision and inguinal lymphadenopathy, hepatomegli, peripheral blood, bone marrow. Fatigue, shortness of breath, acute renal failure, bilateral axalism and inguinal lymphatic, And hepatomegli, pancytopeniaLin et al 2017[12] male, 86Erythematous and vilasus plaques measuring 1.5-5 cm on the skull and on the back - two erythematous and violaceous plaques measuring 5 cm on the skull, 1.5-cm nodule on backHuang et al. 2016 [133] Female female, female 37solytic with a well-demarcated violasius nodul, about 4 cm in diameter, infiltration erythema around the noduleplateal organ felsingal patch on Facetoa et al. 2012 [14] Male, 45multipal spread pure bodies on the trunk, limbs, faceperical blood, bone marrow. On the trunk, limbs, and face, neutropenia, anemia blastic plazacytoid dandritic cell neoplasm (BPDN) is a rare hematologic malignancy with several transmitted purpuric nodules invasive diagnostic course and poor prognosis. Diagnosis is based on cd4+ CD56+, TCL-1+, and blood dandytic cell antigen-2/CD303+ detection of explosions, as well as the absence of offspring specific antigens on tumor cells. In this report we present with extramedicine and bone marrow participation in a case of BPDCN, extensively studied by flow cytometry and immunosocals, who achieved complete remission after acute lymphoblastic leukemia such as chemotherapy and allogenic hematopoietic stem cell transplantation. Introduction The Plastic Plazacytoid Dandritic Cell Neoplasm (BPDN) is a rare invasive hematologic neoplasm, That includes acute myeloid leukemia (AML) and related precursor disorders in the 2008 World Health Organization (WHO) classification of hematological diseases and then classified as a separate unit between myeloid neoplasms in 2016 Revision [1, 2]. Clinical presentation is characterized by a mandarin onset of the disease, which has extramedicine involvement and tropism towards the skin and lymph nodes, followed by systemic diffusion and bone marrow (BM) infiltration [3]. Diagnostics are provided mainly by detecting CD4+ CD56+, TCL-1+, and blood dandytic cell Antigen-2 (BDCA2)/CD303+ lin− explosions [3]. Despite the growing number of reports and biologic insights about BPDCN, the early recognition of the disease still remains a challenge, as its phenotype largely overlaps what is demonstrated by other hematologic fatal people. In this report we present a case of BPDN, in which comprehensive flow cytometry (FCM) and immunohistochemistry (IHC) analyses allowed quick and accurate diagnosis. Case presentation The 37-year-old man was sent to our hospital for a two-month history of skin lesions, followed by moderate hearing loss and nasal closure and, more recently, from the sudden onset of visual impairment and headache. No B symptoms were complained. Physical Examination Lesions such as conjunctivitis, brown nodular scratches on the scalp, neck and back (figures 1(a), 1(b), 1(c), and 1(d)), and bilateral cervical and submandibular lymph nodes enlargement. No hepatospenomegali was found. In otolarynology inspection, hypertrophic obstruction of rhinopherial tract was observed. Ophthalmological evaluation revealed low visual acuity, without retinal or lens abnormality. Laboratory Examination White Blood Cell (WBC) Count 6.0 × 109/L (Neutrophil 59%, Showed lymphocytes 31%, monocytes 9%, and eosinophils 1%), hemoglobin 14.6g/dl, and platelet count 92 × 109/L. Blood chemistry and deposition tests were unremarkable, except for increased lactate dehydrogen levels (348 U/L, general < 225 U/L). Anti-DNA/antinuclear antibodies, circulating immune complexes, were absent and serologic tests for hepatitis B and C viruses were negative. The computed tomography scan exhibits rhinophysiological obstruction by pathological tissue, 2-2.5 cm-sized letterlike, exylary, stomach and inguinal lymph node enlargement, and no brain involvement. Tomography lymph nodes and skin lesions in positron excretion displayed only a slight fluorodeoxyglucos intensify. (a) (b) (c) (d) (a) (b) (c) (d) Skin biopsy showed a diffuse dermal and hypodermal infiltration by immature cells, including irregular nuclei and low cytoplasm, perilular and peridexal patterns, neural structures (figures 2 (a), 2 (b), and 2 (c)). A lymph node biopsy proved the full architectural effacement secondary for mass infiltration by analog cells with the following IHC expression: CD4 + CD10 + CD56 + CD99 + CD123 + CD303 + TdT + BCL2+; CD68PGM1+/− CD7+/− CD43+/− CD2−/+; CD3 − CD5 − CD 8 − CD 20 − CD 30 − CD 79a − CD117 − CD138 − MPO − TIA1 − PAX5 − Cyclind − (Figures 3 and 4). Ki67 expression was 80%. The T-cell receptor (TCR) gamma chain gene resulted in monoclonal. (a) (b) (c) (a) (b) (c) (a) (b) (c) (d) (a) (b) (c) (d) a few days after admission, Signs and symptoms are suddenly deteriorating and peripheral cytopenais (WBC 2.1 × 109/L, HB 10.3 g/dl, and platelets 36 × 109/L) were registered. The presence of blood blemish blasts revealed the presence of 7%, neutrophil 42%, lymphocytes 44%, and monocytes 7%. BM Smear sometimes showed 78% mid-sized explosions with pseudopodia, characterized by the following antigen expression detected by FCM: CD4 + CD10 + CD38 + CD45RA + CD56 + CD123 + HLDR+; CD2−/+ CD7−/+ TdT−/+; CD1a − CD3− CD5− CD8− CD11b − CD11c − CD13−CD14−CD15−CD16−CD19−CD20−CD222−CD25− CD333− CD36− CD6 4− CD66c− CD117− CD138− CD235a − cytCD3− cytCD22− cytCD41− cytCD61− cytCD79a− cytMPO− (Figure 5). Traditional cytogenetics on BM showed normal cariotype, and BCL2 rearrangement was not detected by hybridization and molecular analyses; Heavy chain immunoglobulin genes and TCR gamma chain genes showed polyclonal rearrangement. Cerebrospinal Fluid FCM CD4 + CD10 + CD123 Blast displayed a group of cells, which is consistent with the occult central nervous system An effective steroid debuling, the patient was introduced on acute lymphoblastic leukemia-(all-) like treatment with three courses of hyperclad chemotherapy (partial cyclophosphide, vinchristin, adremycin, and dexamethasone) and concomitant intrathyl prophylaxis (methotrexate, cytorbin, and methylprendilinone); and retrieved the full (CR later he was consolidated with allogenic hematopoitic stem cell transplantation (HSCT) from an unrelated matching donor. Currently, thirteen months after diagnosis, he is still in CR3. DiscussionBPDCN is a very rare and aggressive hematologic malignancy, whose biologic insights and optimal treatment approaches are still under investigation. Various techniques have been employed to address the molecular basis for BPDN. It is believed that the common equivalent of BPDN resides in plasmacytoid dendritic cells (PDCs), mononuclear cells produced in BM and then circulating in blood, lymph nodes and mucosal sites when the immune response is activated [4, 5]. A lot of emphasis has been given on the genesis of PDC. Somewhat developmental and functional asymmetry exists within the population of THE PALC. Indeed, various studies proved evidence that PDC originates from myeloid precursors, but also posted the possibility of partial lymphoid contribution to PDC development [5-7]. Gene expression profiling and sequencing analysis showed that BPDCN shares deregulated genes with both AML and all, but it owns a unique molecular signature, separated by myeloid or lymphide neoplasms[8]. Traditional cytogenetic analysis often shows complex deviations, often chromosome damage such as 5q, 12p13, 13q21, 6q23-ter, 9, but no specific karyotypic abnormalities[9,10]. Many studies have identified mutations in tumor suppressors (RB1, TP53 and CDKN2A), oncogenes (NRAS, KRAS) activism and epigenetic regulators (TET2, TET1, DNMT3A, IDH1, and IHD2) that are often muted even in AML and myelodisplastic syndrome; In addition, mutations have been discovered in iKAROS family genes and ATM aberrations that are commonly found in lymphoid neoplasms [11-15]. Collectively, these data support that the cell of the origin of the tumor may be close to myeloid precursor, but a shared characteristic with lymphoid malignant can not be excluded. Most patients perform a mandarin onset, with strange skin tropism and lymph node involvement, followed by systemic diffusion and BM infiltration. A small percentage of BPDCN is characterized by leukemia presentation in contrast diagnosis [16-21]. Within the spectrum of the disease, various maturity stages of BPDN have been posted based on the expression of CD34 and CD117. In the case of our patient, a double negative subset with a high frequency of extramedicine participation is defined as mature one[22]. On the other hand, our patient showed partial TDT positivity. This conclusion With the previous BPDDN classification, identifying TDT negative cases[23] as more mature. Indeed, TDT expression, registered in one-third of BPDN, can be considered the paramount marker of precursor discrimination[1]. Therefore, our patient's CD34− CD117− TDT + phenotype subgroup does not conform to the definition and suggests the need for further investigation on the matter. At screening, bpddn's immunophenotap largely overlaps like other hematologic fatalities, such as AML, additional nodal nasal type natural killer/T-cell lymphoma, and T-cell leukemia/lymphoma [9, 24]. In our case, CD10 was recorded positivity. CD10 is usually expressed on early, pro/pre-B cells, but also on T/NK cell precursors, later lost during lymphoid differentiation[25]. Even if usually reported as a negative antigen, it has been seen in some reports at BPDCN and occasionally in acute myeloid leukemia [18, 26, 27]. Despite the absence of genealogy antigen expression, CD10 positivity, with TDT expression and the participation of lymphoid tissues, can be confusing for diagnosis in the absence of a comprehensive FCM and IHC characterization. Multiple reports show that chemotherapy like lymphoid is currently the best treatment option for BPDCN, achieving higher response rates; The efficacy of all protocols can be sustained by the regulation of genes that herald sensitivity to methotrexate, prednisone and vincristine. However, unlike the majority of lymphide fatalities, traditional chemotherapy alone does not appear to be sufficient to ensure sustainable long-term emissions, with an initial regeneration rate of around 60% of patients receiving CR [17, 21, 28]. As such, our patient demonstrated an excellent response to hyperquad chemotherapy that was further consolidated with allogenic HSCT. In fact, retrospective case reports and available information from single-institution experiences show that adults may benefit from allogenic HSCT in the first CR, which can achieve long-term survival with both myeloablative and low-intensity conditioning resistance [17, 29-31]. In addition, novel potential therapeutic targets have been identified, such as BCL-2, an antiapotopotic protein is usually more expressed in BPDCN, as in our case [8, 16, 32, 33]. The chance to find effective targeted treatments further strengthens the need for a full characterization of this neoplasm. Conflicts of Interest authors declare that there are no conflicts of interest regarding the publication of this paper. Copyright © 2017 Martina Penisi et al. It is an open access article distributed under the Creative Commons Attribution License, which allows unrestricted use, distribution and reproduction in any medium, provided the original function is properly quoted. Quoted.